MannKind Corporation
Westlake Village, Los Angeles, CA
2
staff members
Company Profile
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza? (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Mission:?To give people control over their health and the freedom to live life.
201 to 500
TypeCompany - Public (MNKD)
Revenue$10 to $25 million (USD) per year
IndustryBiotech & Pharmaceuticals
CompetitorsEli Lilly and Company, Medtronic, Novo Nordisk
Founded1991
Company site
Share Profile
Staff Members
CEO
Worked since Sunday, Nov 30 2025
-
ManagerWorked since - -
CEOWorked since -
People Also Viewed
-
2121 Rosecrans Avenue Suite-6300, El Segundo, California, United StatesCompany size: 101-250 -
Chicago, ILCompany size: 1 to 50 -
Parsippany, NJCompany size: Unknown -
Los Angeles, CACompany size: 1 to 50 -
Los Angeles, CA (US)Company size: 1 to 50 -
Denver, COCompany size: 51 to 200
Claim business page
Only the CEO can claim this profile. If you are the CEO, first
claim your profile and then claim your business page.
